Cleaved-C1S (R437) Antibody

What is the Cleaved-C1s (R437) Antibody and what epitope does it recognize?

The Cleaved-C1s (R437) Antibody is a polyclonal antibody typically derived from rabbit that specifically recognizes the cleaved fragment of the C1s heavy chain (HC) protein resulting from proteolytic cleavage adjacent to arginine 437 (R437) . The immunogen used for antibody generation is a synthesized peptide derived from human C1S, spanning amino acids 388-437 . This antibody is designed to detect endogenous levels of the activated C1s HC protein fragment, making it valuable for studying complement activation .

What is the biological significance of C1s in the complement system?

C1s is a critical serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system . The activation process begins when C1r activates C1s, which then cleaves and activates C2 and C4 complement components . This activation forms the classical C3 convertase (C4bC2b), which cleaves plasma C3 into C3a and C3b fragments . C1s also cleaves insulin-like growth factor binding protein 5 (IGFBP5), thereby inhibiting the trophic effects of IGF1, indicating functions beyond complement activation .

How does cleaved C1s differ functionally from uncleaved C1s?

Cleaved C1s represents the activated form of the protein, possessing serine protease activity necessary for downstream complement activation . The cleavage at R437 is essential for exposing the catalytic site of C1s, enabling it to cleave its substrates C2 and C4 . When C1s is activated, it catalyzes the cleavage of Arg-|-Ala bond in complement component C4 to form C4a and C4b, and Lys(or Arg)-|-Lys bond in complement component C2 to form C2a and C2b, which establishes the 'classical' pathway C3 convertase . Detection of this cleaved form provides direct evidence of classical complement pathway activation .

What are the recommended applications for Cleaved-C1s (R437) Antibody?

The Cleaved-C1s (R437) Antibody is primarily validated for Western Blot (WB) and ELISA applications . The recommended dilution ratios are:

• Western Blot: 1:500 - 1:2000

• ELISA: 1:20000

While these are the established applications, the antibody has not been extensively tested in other techniques such as immunohistochemistry, immunofluorescence, or immunoprecipitation, though related C1s antibodies have shown efficacy in these methods .

What sample types can be effectively analyzed with this antibody?

The Cleaved-C1s (R437) Antibody demonstrates reactivity with human and rat samples, with some products also reporting reactivity with mouse samples . Given the role of C1s in the complement system, appropriate sample types include serum, plasma, tissue homogenates (particularly liver, where C1s is primarily expressed), and peripheral blood leukocytes . When working with serum samples, it's important to note that anticoagulants (EDTA, citrate, and heparin) can inhibit the enzymatic ability of activated C1s .

What is the optimal protocol for detecting cleaved C1s in serum samples?

For optimal detection of activated C1s in serum samples, a fluorescence resonance energy transfer (FRET)-based immunoassay has been established with the following performance characteristics:

• Linear quantification range: up to 10 μmol min^-1 mL^-1

• Limit of detection (LOD): 0.096 μmol·min^-1·mL^-1

• Recovery range: 90% ~ 110%

• Coefficient of variation (CV): <10% for both intra-analysis and inter-analysis

When implementing this method:

• Use fresh serum samples without anticoagulants

• Establish proper controls for calibration

• Be aware that bilirubin (0.2 mg mL^-1), chyle (2000 FTU), and hemoglobin (5 mg mL^-1) do not significantly interfere with the assay

How should the antibody be stored and handled to maintain efficacy?

The Cleaved-C1s (R437) Antibody should be stored at -20°C to -25°C for optimal stability (up to 1 year from the date of receipt) . The antibody is typically formulated as a liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide . Avoid repeated freeze-thaw cycles as this can degrade antibody performance . When working with the antibody, keep it on ice and return to storage promptly after use.

How can the Cleaved-C1s (R437) Antibody be used to study complement activation in disease models?

The Cleaved-C1s (R437) Antibody offers a valuable tool for investigating classical complement pathway activation in various disease models, particularly autoimmune conditions and inflammatory disorders . Researchers can use this antibody to:

• Quantify C1s activation levels in patient samples, correlating with disease severity

• Monitor complement activation following therapeutic interventions

• Study the dysregulation of classical pathway activation in autoimmune diseases

• Investigate antibody-dependent complement activity in both pathological contexts and protective immune responses

Since C1s deficiency is associated with early-onset multiple autoimmune diseases, this antibody can help elucidate the pathophysiological mechanisms involved .

What considerations should be made when designing experiments to study antibody-dependent complement activation?

When investigating antibody-dependent complement activation using the Cleaved-C1s (R437) Antibody, several factors should be considered:

• Antibody clustering factors: The structure of C1q facilitates sustained cascade initiation upon specific target recognition. Important considerations include:

  • Antigen expression level, spatial distribution, and membrane mobility

  • Antibody factors such as antigen-binding and Fc valency

  • Epitope placement, angle of binding, and hinge flexibility between antigen-binding and C1q-binding domains

• Balance of activation and inhibition: The net magnitude of complement activation depends on the balance between pathway activation complexes and complement inhibitory factors .

• Sample preparation: Ensure samples are collected and processed appropriately to preserve the native state of complement proteins. Avoid anticoagulants when studying C1s activity .

How does the FRET-based immunoassay for C1s activity determination compare with traditional methods?

The FRET-based immunoassay for quantitative detection of activated C1s represents an advancement over traditional methods with several key advantages:

The FRET-based method enables direct quantification of C1s enzymatic activity rather than merely detecting protein presence, providing more functional information about complement activation status .

What are common issues when using Cleaved-C1s (R437) Antibody in Western blots?

When using Cleaved-C1s (R437) Antibody in Western blot applications, researchers might encounter several challenges:

• Multiple banding patterns: The C1s protein has observed molecular weights of 47kD and 76kD . Multiple bands may represent different cleavage products or glycosylation states.

• Weak signal: If signal is weak, consider:

  • Increasing primary antibody concentration (within recommended range)

  • Extending incubation time

  • Optimizing protein loading amount

  • Using enhanced chemiluminescence detection systems

• High background: To reduce background:

  • Increase blocking time or concentration

  • Use more stringent washing conditions

  • Decrease primary antibody concentration

  • Ensure sample preparation minimizes non-specific binding proteins

• Inconsistent results with different sample types: C1s expression and cleavage patterns may vary between tissue types and disease states. Always include appropriate positive controls .

How should researchers validate the specificity of the Cleaved-C1s (R437) Antibody?

To validate the specificity of the Cleaved-C1s (R437) Antibody, researchers should implement the following approaches:

• Positive controls: Use samples known to contain activated C1s, such as complement-activated serum.

• Negative controls: Include samples where C1s activation is inhibited or absent, such as EDTA-treated serum (which inhibits complement activation) .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity.

• Parallel analysis: Compare results with other C1s antibodies that target different epitopes to confirm specific detection of the cleaved form.

• Enzymatic activity correlation: Correlate antibody signal with functional assays measuring C1s enzymatic activity to confirm that the detected protein represents active C1s .

How is Cleaved-C1s (R437) Antibody contributing to complement system research?

The Cleaved-C1s (R437) Antibody is advancing complement system research in several areas:

• Quantitative complement activation assessment: The development of quantitative assays for activated C1s enables more precise measurement of classical pathway activation in research and potentially clinical settings .

• Autoimmune disease mechanisms: Since C1s deficiency is associated with autoimmune diseases, detecting activated C1s helps elucidate the role of complement in autoimmunity .

• Therapeutic development: Understanding C1s activation mechanisms supports the development of complement-targeted therapeutics for conditions involving dysregulated complement activation .

• Non-complement functions: Investigation of C1s cleavage of IGFBP5 and subsequent inhibition of IGF1 trophic effects points to functions beyond complement activation that may be relevant in various physiological and pathological contexts .

What emerging applications exist for monitoring C1s activation in clinical research?

Emerging applications for monitoring C1s activation using tools like the Cleaved-C1s (R437) Antibody include:

• Biomarker development: Activated C1s levels may serve as biomarkers for complement-mediated diseases, potentially aiding in diagnosis, prognosis, or therapeutic monitoring .

• Cancer immunotherapy: Antibody-dependent complement activation plays a role in anti-tumor efficacy, and monitoring C1s activation could help predict or monitor response to antibody therapies .

• Autoantibody-mediated disorders: C4b, a product of C1s activity, is used as a tissue biomarker in autoantibody-mediated pathology diagnoses. More direct measurement of C1s activation could provide additional diagnostic information .

• Antibody-drug conjugate (ADC) research: Understanding complement activation is important in developing ADCs with optimal efficacy and safety profiles .

The continued refinement of methods to detect and quantify activated C1s will likely expand these applications, potentially transitioning some from research to clinical utility.